Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19
BIOpreparations. Prevention, Diagnosis, Treatment
; 22(4):414-434, 2022.
Article
in Russian
| EMBASE | ID: covidwho-2245175
ABSTRACT
Finding effective and safe medicines to fight SARS-CoV-2 infection is an urgent task. RPH-137 is an original trap fusion protein against SARS-CoV-2 virus. It comprises the angiotensin-converting enzyme type 2 extracellular domain and the human IgG1 Fc fragment. The aim of the study was to carry out a preclinical evaluation of the efficacy of RPH-137 and molnupiravir against SARS-CoV-2 infection. Materials and methods:
the authors analysed RPH-137 expressed in a stable CHO cell line and molnupiravir used as an active pharmaceutical ingredient. Drug-mediated inhibition of virus-induced cytotoxicity was assessed in Vero cell culture. In vivo efficacy assessments were performed in Syrian hamsters. The animals were infected intranasally with SARS-CoV-2 (PIK35 clinical isolate) in the dose of 5 log TCID50. The authors evaluated body weight measurements, lung-body weight ratios, and lung histopathology findings and determined viral RNA levels in oropharyngeal swabs by RT-PCR using the amplification cycle threshold (Ct). The statistical analyses involved one- and two-way ANOVA, Student's t-test, and Mann–Whitney test.Results:
RPH-137 and molnupiravir inhibited the cytopathic effect of SARS-CoV-2 in Vero cells;the EC50 values of RPH-137 amounted to 4.69 μg/mL (21.3 nM) and 16.24 μg/mL (73.8 nM) for 50 TCID50 and 200 TCID50, respectively, whereas the EC50 values of molnupiravir were 0.63 μg/mL (1900 nM) for both doses. Intramuscular RPH-137 (30 and 80 mg/kg) had no effect on the infection process in Syrian hamsters. The comparison with the challenge control group showed that intraperitoneal RPH-137 (100 mg/kg) had statistically significant effects on a number of parameters, including a 27% reduction in inflammation and a 30% reduction in the total lesion area of the lungs by Day 7. Intragastric molnupiravir (300 mg/kg twice daily) significantly inhibited SARS-CoV-2 infection.Conclusions:
both RPH-137 and molnupiravir inhibited the cytopathic effect of SARS-CoV-2 in Vero cells. In Syrian hamsters, molnupiravir demonstrated a more pronounced inhibition of SARS-CoV-2 than RPH-137. However, RPH-137 had statistically significant effects on a range of parameters. This offers additional perspectives for further research.
analysis of variance; animal cell; animal experiment; antiviral activity; article; body weight; CHO cell line; comparative effectiveness; controlled study; coronavirus disease 2019; cytopathogenic effect; drug therapy; EC50; gene amplification; histopathology; human; inflammation; nonhuman; oropharyngeal swab; polymerase chain reaction; preclinical study; rank sum test; relative lung weight; SARS-CoV-2 (clinical isolate PIK35); Severe acute respiratory syndrome coronavirus 2; Syrian hamster; TCID50; Vero cell line; fusion protein; molnupiravir; virus RNA
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Russian
Journal:
BIOpreparations. Prevention, Diagnosis, Treatment
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS